Product Image

Contributor Information

  • Name Anne Lykkesfeldt
  • Institute Danish Cancer Society, Denmark

Tool Details

  • Tool name: MCF7/TAMR-4 Cell Line
  • Alternate names: MCF-7/TAMR-4 Cell Line
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MCF7 S0.5
  • Organism: Human
  • Tissue: Breast
  • Gender: Female
  • Cancer type: Breast cancer
  • Disease: Cancer
  • Model: Tumour line
  • Conditional: Yes
  • Application: Investigate signalling pathways involved in tamoxifen resistance
  • Description: MCF7/TAMR-4 cell line is a stable tamoxifen-resistant subline. This cell line has been established in tissue culture after long term treatment with 1 uM tamoxifen. Tamoxifen (Nolvadex) is a widely used drug for hormone-dependent cancer. Tamoxifen resistance (either primary or acquired) makes oestrogen receptor-positive breast cancer much more difficult to treat.

    This cell line was produced from the parental cell line MCF7/S0.5, as a model cell system to study the effects of tamoxifen resistant cancer growth. Tamoxifen-resistant cells are passaged continuously in the presence of 1 uM tamoxifen. This concentration is lethal for the parental cell line. MCF7/TAMR-4 cells are oestrogen receptor positive and progesterone receptor negative. They are growth inhibited by the pure antioestrogen fulvestrant.

    Previous applications of this cell line include treatment with steroidal antiestrogens.

    MCF7/TAMR-4 enables identification of new hormone therapies and greater understanding of the signalling pathways/methods behind tamoxifen resistance. Additionally MCF/TAMR-4 can aid in identifying new predictive markers for response to hormonal therapy.
  • Research area: Cancer; Drug development
  • Production details: The parental cell line for the MCF7/TAMR-4 cells is MCF7/S0.5, which was adapted to grow at low serum concentration in order to study the effect of estradiol and tamoxifen. MCF7/TAMR-4 has been established from a clone of cells that survived long term treatment with 1 uM tamoxifen. Tamoxifen-resistant cells are passaged continuously in presence of 1 uM tamoxifen, which is lethal for the parental MCF7/S0.5 cell line.
  • Cellosaurus ID: CVCL_1D42
  • Additional notes: MCF7/TAMR-4 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-4 cells are growth inhibited by the pure antiestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-4 cell, ref 1. Treatment targeting the Aurora kinase A restores sensitivity to tamoxifen treatment. The TAMR lines were established from the MCF7/S0.5 cell line, which was adapted to grow with 0.5% fetal calf serum in phenol red containing DMEM/F12 medium. Treatment with tamoxifen was started in passage 351. Few colonies of cells survived the treatment and after 28 days of tamoxifen treatment, tamoxifen was omitted from the medium for 22 days. After 19 passages without tamoxifen (passage 372) the cells underwent a second treatment with tamoxifen which initially reduced cell growth rate, but around 390-400 the growth rate of the tamoxifen resistant cell lines was close to the growth rate of the parental MCF7/S0.5 cells.

  • For Research Use Only

Target Details

  • Target: Oestrogen receptor

Application Details

  • Application: Investigate signalling pathways involved in tamoxifen resistance
  • Application notes: MCF7/TAMR-4 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-4 cells are growth inhibited by the pure antiestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-4 cell, ref 1. Treatment targeting the Aurora kinase A restores sensitivity to tamoxifen treatment. The TAMR lines were established from the MCF7/S0.5 cell line, which was adapted to grow with 0.5% fetal calf serum in phenol red containing DMEM/F12 medium. Treatment with tamoxifen was started in passage 351. Few colonies of cells survived the treatment and after 28 days of tamoxifen treatment, tamoxifen was omitted from the medium for 22 days. After 19 passages without tamoxifen (passage 372) the cells underwent a second treatment with tamoxifen which initially reduced cell growth rate, but around 390-400 the growth rate of the tamoxifen resistant cell lines was close to the growth rate of the parental MCF7/S0.5 cells. Passage 402 (AL3482), 403 (AL2753)

Handling

  • Format: Frozen
  • Passage number: Passage 402 (AL3482), 403 (AL2753)
  • Growth medium: DMEM:Ham's F-12 phenol red-free medium containing 1% fetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 uM).
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

Related Tools

Product Image

OAW42A cell line

#157984
Product Image

Transient receptor potential cation channel superfamily M member 2 (TRPM2)-GFP HeLa cell line

#158382
Product Image

CuFi-1 cell line

#154445

References

  • •  Joshi et al. 2016. Oncotarget. 7(35):57239-57253. PMID: 27528030.
  • •  Elias et al. 2015. Oncogene. 34(15):1919-1927. PMID: 24882577.
  • •  Thrane et al. 2014. Oncogene. PMID: 25362855.
  • •  Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.
  • •  Cutrupi et al. 2012. Oncogene. 31(40):4353-4361. PMID: 22249258.
  • •  Millour et al. 2010. Oncogene. 29(20):2983-2995. PMID: 20208560.
  • •  Pancholi et al. 2008. Endocr Relat Cancer. 15(4):985-1002. PMID: 18824559.
  • •  Sarwar et al. 2006. Endocr Relat Cancer. 13(3):851-861. PMID: 16954434.